

Anna Sophie Berghoff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2097867/publications.pdf>

Version: 2024-02-01

149
papers

6,936
citations

81839

39
h-index

71651

76
g-index

150
all docs

150
docs citations

150
times ranked

10224
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic factors in adult brainstem glioma: a tertiary care center analysis and review of the literature. <i>Journal of Neurology</i> , 2022, 269, 1574-1590.	1.8	10
2	Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations. <i>JAMA Oncology</i> , 2022, 8, 106.	3.4	53
3	Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 years. <i>European Journal of Cancer</i> , 2022, 162, 170-181.	1.3	18
4	EV11 Promotes the Proliferation and Invasive Properties of Human Head and Neck Squamous Cell Carcinoma Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1050.	1.8	3
5	New Approaches with Precision Medicine in Adult Brain Tumors. <i>Cancers</i> , 2022, 14, 712.	1.7	2
6	Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events – a retrospective cohort study. <i>European Journal of Cancer</i> , 2022, 165, 184-194.	1.3	29
7	Prognostic impact of genetic alterations and methylation classes in meningioma. <i>Brain Pathology</i> , 2022, 32, e12970.	2.1	27
8	SARS-CoV-2-related mortality and treatment delays for cancer patients in Austria. <i>Wiener Klinische Wochenschrift</i> , 2022, , 1.	1.0	2
9	DNA Methylation Associates With Clinical Courses of Atypical Meningiomas: A Matched Case–Control Study. <i>Frontiers in Oncology</i> , 2022, 12, 811729.	1.3	2
10	DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma. , 2022, 10, e003420.		11
11	Active immunization with a Her-2/neu-targeting Multi-peptide B cell vaccine prevents lung metastases formation from Her-2/neu breast cancer in a mouse model. <i>Translational Oncology</i> , 2022, 19, 101378.	1.7	5
12	Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron. <i>Cancer Cell</i> , 2022, 40, 444-446.	7.7	28
13	Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210962.	1.4	21
14	Brain metastases in metastatic cancer: a review of recent advances in systemic therapies. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 325-339.	1.1	10
15	A basic review on systemic treatment options in WHO grade II-III gliomas. <i>Cancer Treatment Reviews</i> , 2021, 92, 102124.	3.4	44
16	Local blood coagulation drives cancer cell arrest and brain metastasis in a mouse model. <i>Blood</i> , 2021, 137, 1219-1232.	0.6	31
17	Systemic inflammation scores correlate with survival prognosis in patients with newly diagnosed brain metastases. <i>British Journal of Cancer</i> , 2021, 124, 1294-1300.	2.9	21
18	Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110090.	1.4	9

#	ARTICLE	IF	CITATIONS
19	Evaluation of the Temporal Muscle Thickness as an Independent Prognostic Biomarker in Patients with Primary Central Nervous System Lymphoma. <i>Cancers</i> , 2021, 13, 566.	1.7	21
20	Prognostic Value of 5-ALA Fluorescence, Tumor Cell Infiltration and Angiogenesis in the Peritumoral Brain Tissue of Brain Metastases. <i>Cancers</i> , 2021, 13, 603.	1.7	12
21	Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients. , 2021, 9, e001458.		26
22	LAG-3 expression in the inflammatory microenvironment of glioma. <i>Journal of Neuro-Oncology</i> , 2021, 152, 533-539.	1.4	22
23	Prognostic factors in leptomeningeal metastases. <i>Neuro-Oncology</i> , 2021, 23, 1208-1209.	0.6	0
24	Systemic and local inflammation characteristics in patients with cancer after lung transplantation.. <i>Journal of Clinical Oncology</i> , 2021, 39, e14527-e14527.	0.8	0
25	Brain metastases: new systemic treatment approaches. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 198-203.	0.3	3
26	Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3643-3650.	2.0	10
27	5-ALA Fluorescence Is a Powerful Prognostic Marker during Surgery of Low-Grade Gliomas (WHO) Tj ETQq1 1 0.784314 rgBT /Overlo	1.7	19
28	Development of Randomized Trials in Adults with Medulloblastomaâ€”The Example of EORTC 1634-BTG/NOA-23. <i>Cancers</i> , 2021, 13, 3451.	1.7	8
29	SARS-CoV-2 screening in cancer outpatients during the second wave of the COVID-19 pandemic. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 909-914.	1.0	2
30	Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors. <i>Neuro-Oncology</i> , 2021, 23, 1100-1112.	0.6	59
31	Thyroid Hormone Replacement Therapy Is Associated with Longer Overall Survival in Patients with Resectable Gastroesophageal Cancer: A Retrospective Single-Center Analysis. <i>Cancers</i> , 2021, 13, 5050.	1.7	0
32	Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. <i>Journal of Clinical Oncology</i> , 2021, 39, 3839-3852.	0.8	93
33	ASCO 2021: Highlights in central nervous system tumors. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 323-327.	0.3	1
34	Precision medicine biomarkers in brain metastases: applications, discordances, and obstacles. <i>Neuro-Oncology Advances</i> , 2021, 3, v35-v42.	0.4	2
35	Reply to Stummer, W.; Thomas, C. Comment on â€œHosmann et al. 5-ALA Fluorescence Is a Powerful Prognostic Marker during Surgery of Low-Grade Gliomas (WHO Grade II)â€”Experience at Two Specialized Centers. <i>Cancers</i> 2021, 13, 2540â€”Cancers, 2021, 13, 5705.	1.7	0
36	Efficacy, Outcome, and Safety of Elderly Patients with Glioblastoma in the 5-ALA Era: Single Center Experience of More Than 10 Years. <i>Cancers</i> , 2021, 13, 6119.	1.7	6

#	ARTICLE	IF	CITATIONS
37	Noninvasive Differentiation of Meningiomas and Dural Metastases Using Intratumoral Vascularity Obtained by Arterial Spin Labeling. <i>Clinical Neuroradiology</i> , 2020, 30, 599-605.	1.0	5
38	The PERSONS score: A new tool for cancer patientsâ€™ symptom assessment in simultaneous care and home care settings. <i>Palliative and Supportive Care</i> , 2020, 18, 33-38.	0.6	4
39	41. PROGNOSTIC VALIDATION OF THE EANO ESMO CLASSIFICATION OF LEPTOMENINGEAL METASTASIS. <i>Neuro-Oncology Advances</i> , 2020, 2, ii7-ii8.	0.4	0
40	Neurological symptom burden impacts survival prognosis in patients with newly diagnosed nonâ€“small cell lung cancer brain metastases. <i>Cancer</i> , 2020, 126, 4341-4352.	2.0	27
41	Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours. <i>ESMO Open</i> , 2020, 5, e000863.	2.0	17
42	Postoperative Magnetic Resonance Imaging After Surgery of Brain Metastases: Analysis of Extent of Resection and Potential Risk Factors for Incomplete Resection. <i>World Neurosurgery</i> , 2020, 143, e365-e373.	0.7	7
43	SARS-CoV-2 Testing in Patients With Cancer Treated at a Tertiary Care Hospital During the COVID-19 Pandemic. <i>Journal of Clinical Oncology</i> , 2020, 38, 3547-3554.	0.8	40
44	SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic. <i>ESMO Open</i> , 2020, 5, e000889.	2.0	39
45	Nintedanib and a bi-specific anti-VEGF/Ang2 nanobody selectively prevent brain metastases of lung adenocarcinoma cells. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 637-648.	1.7	15
46	Sarcopenia in Neurological Patients: Standard Values for Temporal Muscle Thickness and Muscle Strength Evaluation. <i>Journal of Clinical Medicine</i> , 2020, 9, 1272.	1.0	56
47	Clinical characteristics and prognostic factors of adult patients with pilocytic astrocytoma. <i>Journal of Neuro-Oncology</i> , 2020, 148, 187-198.	1.4	25
48	Perioperative imaging in patients treated with resection of brain metastases: a survey by the European Association of Neuro-Oncology (EANO) Youngsters committee. <i>BMC Cancer</i> , 2020, 20, 410.	1.1	14
49	Venous thromboembolic events in patients with brain metastases: the PICOS score. <i>European Journal of Cancer</i> , 2020, 134, 75-85.	1.3	11
50	Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. <i>Nature Genetics</i> , 2020, 52, 371-377.	9.4	177
51	Hypothyroidism correlates with favourable survival prognosis in patients with brain metastatic cancer. <i>European Journal of Cancer</i> , 2020, 135, 150-158.	1.3	10
52	CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. <i>Acta Neuropathologica</i> , 2020, 140, 409-413.	3.9	116
53	Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa038.	0.4	14
54	Does the application of diffusion weighted imaging improve the prediction of survival in patients with resected brain metastases? A retrospective multicenter study. <i>Cancer Imaging</i> , 2020, 20, 16.	1.2	8

#	ARTICLE	IF	CITATIONS
55	Viennese risk prediction score for Advanced Gastroesophageal carcinoma based on Alarm Symptoms (VAGAS score): characterisation of alarm symptoms in advanced gastro-oesophageal cancer and its correlation with outcome. ESMO Open, 2020, 5, e000623.	2.0	4
56	Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma. ESMO Open, 2020, 5, e000647.	2.0	4
57	Lymphocyte-activation gene 3 (LAG-3) expression in the inflammatory microenvironment of glioma.. Journal of Clinical Oncology, 2020, 38, 2553-2553.	0.8	4
58	Detailed analysis of 5-aminolevulinic acid induced fluorescence in different brain metastases at two specialized neurosurgical centers: experience in 157 cases. Journal of Neurosurgery, 2020, 133, 1032-1043.	0.9	19
59	DNA methylation profiling in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors.. Journal of Clinical Oncology, 2020, 38, e18527-e18527.	0.8	1
60	Radiation-induced changes in the inflammatory microenvironment composition of lung cancer brain metastases.. Journal of Clinical Oncology, 2020, 38, 2528-2528.	0.8	0
61	Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field. ESMO Open, 2020, 5, e000880.	2.0	4
62	Evaluation of an Assay for MGMT Gene Promoter Methylation in Glioblastoma Samples. Anticancer Research, 2020, 40, 6229-6236.	0.5	1
63	NCOG-02. PROGNOSTIC VALIDATION OF THE EANO ESMO CLASSIFICATION OF LEPTOMENINGEAL METASTASIS. Neuro-Oncology, 2020, 22, ii129-ii129.	0.6	1
64	The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study. Palliative and Supportive Care, 2019, 17, 82-86.	0.6	4
65	New emerging targets in cancer immunotherapy: the role of Cluster of Differentiation 40 (CD40/TNFR5). ESMO Open, 2019, 4, e000510.	2.0	65
66	Prognostic assessment in patients with newly diagnosed small cell lung cancer brain metastases: results from a real-life cohort. Journal of Neuro-Oncology, 2019, 145, 85-95.	1.4	13
67	Quantitative evidence for early metastatic seeding in colorectal cancer. Nature Genetics, 2019, 51, 1113-1122.	9.4	315
68	Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion. ESMO Open, 2019, 4, e000498.	2.0	38
69	Does neoadjuvant anti-PD1 therapy improve glioblastoma outcome?. Nature Reviews Neurology, 2019, 15, 314-315.	4.9	13
70	New emerging targets in cancer immunotherapy: CD27 (TNFRSF7). ESMO Open, 2019, 4, e000629.	2.0	78
71	Awareness of predatory journals and open access among medical oncologists: results of an online survey. ESMO Open, 2019, 4, e000580.	2.0	15
72	Low Systemic Levels of Chemokine C-C Motif Ligand 3 (CCL3) are Associated with a High Risk of Venous Thromboembolism in Patients with Glioma. Cancers, 2019, 11, 2020.	1.7	13

#	ARTICLE	IF	CITATIONS
73	Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey. <i>European Journal of Cancer</i> , 2018, 93, 37-46.	1.3	69
74	Large-scale database mining reveals hidden trends and future directions for cancer immunotherapy. <i>Oncotimmunology</i> , 2018, 7, e1444412.	2.1	11
75	Diagnostic value of 18F-fluorodesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site. <i>European Journal of Cancer</i> , 2018, 96, 64-72.	1.3	17
76	Anti-angiogenic therapies in brain metastases. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 14-17.	0.3	26
77	Role of the blood-brain barrier in metastatic disease of the central nervous system. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 149, 57-66.	1.0	22
78	High correlation of temporal muscle thickness with lumbar skeletal muscle cross-sectional area in patients with brain metastases. <i>PLoS ONE</i> , 2018, 13, e0207849.	1.1	63
79	Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p. <i>Acta Neuropathologica</i> , 2018, 136, 975-978.	3.9	11
80	Intertumoral Heterogeneity in SCLC Is Influenced by the Cell Type of Origin. <i>Cancer Discovery</i> , 2018, 8, 1316-1331.	7.7	123
81	New developments in brain metastases. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641878550.	1.5	25
82	Temporal muscle thickness is an independent prognostic marker in melanoma patients with newly diagnosed brain metastases. <i>Journal of Neuro-Oncology</i> , 2018, 140, 173-178.	1.4	62
83	PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome. <i>Histopathology</i> , 2018, 73, 573-584.	1.6	68
84	Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases - development and validation of the LabBM score. <i>Neuro-Oncology</i> , 2017, 19, now290.	0.6	26
85	Correlation of immune phenotype with IDH mutation in diffuse glioma. <i>Neuro-Oncology</i> , 2017, 19, 1460-1468.	0.6	213
86	Targeted Therapies for Melanoma Brain Metastases. <i>Current Treatment Options in Neurology</i> , 2017, 19, 13.	0.7	28
87	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , The, 2017, 18, 682-694.	5.1	586
88	Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases. <i>European Radiology</i> , 2017, 27, 3167-3173.	2.3	80
89	Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e116-e122.	1.8	65
90	Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers. <i>ESMO Open</i> , 2016, 1, e000024.	2.0	152

#	ARTICLE	IF	CITATIONS
91	Tumor-infiltrating lymphocyte subsets and tertiary lymphoid structures in pulmonary metastases from colorectal cancer. <i>Clinical and Experimental Metastasis</i> , 2016, 33, 727-739.	1.7	65
92	Impact of Blood-Brain Barrier Integrity on Tumor Growth and Therapy Response in Brain Metastases. <i>Clinical Cancer Research</i> , 2016, 22, 6078-6087.	3.2	109
93	In search of a target: PD-1 and PD-L1 profiling across glioma types. <i>Neuro-Oncology</i> , 2016, 18, 1331-1332.	0.6	18
94	Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC). <i>Journal of Neuro-Oncology</i> , 2016, 130, 19-29.	1.4	107
95	Psyche at the end of life: Psychiatric symptoms are prevalent in patients admitted to a palliative care unit. <i>Palliative and Supportive Care</i> , 2016, 14, 250-258.	0.6	7
96	A Cross-Sectional Study of Patients' Satisfaction With Totally Implanted Access Ports. <i>Clinical Journal of Oncology Nursing</i> , 2016, 20, 175-180.	0.3	12
97	Association of TP53 mutations with TP53 codon 72 polymorphism and outcome in triple-negative breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2016, 9, 70-75.	0.3	0
98	Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. <i>Oncolmmunology</i> , 2016, 5, e1057388.	2.1	239
99	Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. <i>Neuro-Oncology</i> , 2016, 18, 401-407.	0.6	53
100	Expression profiling of angiogenesis-related genes in brain metastases of lung cancer and melanoma. <i>Tumor Biology</i> , 2016, 37, 1173-1182.	0.8	39
101	Descriptive analysis of 2419 patients with brain metastases of solid cancers: A real life cohort. <i>Journal of Clinical Oncology</i> , 2016, 34, 2072-2072.	0.8	1
102	Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals <i>cMet</i> as a negative prognostic factor. <i>Histopathology</i> , 2015, 67, 799-805.	1.6	10
103	Assessing <i>MGMT</i> methylation status and its current impact on treatment in glioblastoma. <i>CNS Oncology</i> , 2015, 4, 47-52.	1.2	24
104	Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, e41-55.	1.8	49
105	Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma. <i>European Journal of Cancer</i> , 2015, 51, 1803-1811.	1.3	36
106	Atypical sporadic <i>CJD</i> phenotype with white matter kuru plaques associated with intranuclear inclusion body and argyrophilic grain disease. <i>Neuropathology</i> , 2015, 35, 336-342.	0.7	11
107	Haematopoietic stem cell transplantation for treatment of primary <i>CNS</i> lymphoma: single-centre experience and literature review. <i>European Journal of Haematology</i> , 2015, 95, 75-82.	1.1	10
108	Brain tumour cells interconnect to a functional and resistant network. <i>Nature</i> , 2015, 528, 93-98.	13.7	787

#	ARTICLE	IF	CITATIONS
109	The future of targeted therapies for brain metastases. <i>Future Oncology</i> , 2015, 11, 2315-2327.	1.1	6
110	Activity of T-DM1 in Her2-positive breast cancer brain metastases. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 729-737.	1.7	103
111	Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. <i>Histopathology</i> , 2015, 66, 289-299.	1.6	99
112	Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1064-1075.	0.6	485
113	Plasma PD-L1 concentration in patients with brain metastases from solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, e13026-e13026.	0.8	3
114	Correlation of plasma PD-L1 detectability with age in glioma patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, e13039-e13039.	0.8	1
115	The inflammatory microenvironment in brain metastases: potential treatment target?. <i>Chinese Clinical Oncology</i> , 2015, 4, 21.	0.4	51
116	Effect of laboratory parameters on prognostic value in patients with newly diagnosed brain metastases: Analysis of 1,207 cases.. <i>Journal of Clinical Oncology</i> , 2015, 33, e13034-e13034.	0.8	0
117	Prognostic impact of breast cancer (BC) subtype in elderly patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20536-e20536.	0.8	0
118	Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer. <i>Breast Care</i> , 2014, 9, 6-6.	0.8	8
119	Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues. <i>Acta Neuropathologica</i> , 2014, 128, 879-891.	3.9	54
120	High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer. <i>Lung Cancer</i> , 2014, 83, 83-89.	0.9	63
121	ALKgene aberrations and the JUN/JUNB/PDGFR axis in metastatic NSCLC. <i>Apmis</i> , 2014, 122, 867-872.	0.9	6
122	α 23, α 25 and α 26 integrins in brain metastases of lung cancer. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 841-851.	1.7	51
123	Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients. <i>Breast</i> , 2014, 23, 637-643.	0.9	56
124	Alleviation of Brain Edema and Restoration of Functional Independence by Bevacizumab in Brain-Metastatic Breast Cancer: A Case Report. <i>Breast Care</i> , 2014, 9, 134-134.	0.8	25
125	Association of <i>TP53</i> codon 72 polymorphism with <i>TP53</i> mutation in triple-negative breast cancer (TNBC) patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1130-1130.	0.8	1
126	PD1 and PD-L1 expression in glioblastoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2011-2011.	0.8	4

#	ARTICLE	IF	CITATIONS
127	Association of tumor-infiltrating lymphocytes with brain edema and overall survival in brain metastases.. Journal of Clinical Oncology, 2014, 32, 2012-2012.	0.8	1
128	T-DM1 in HER2-positive breast cancer brain metastases (BM).. Journal of Clinical Oncology, 2014, 32, 650-650.	0.8	1
129	A cross-section study evaluating patientsâ€™ satisfaction with totally implanted access ports (PAC) assessing the PAC-related complication rate at two tertiary care centres in Austria.. Journal of Clinical Oncology, 2014, 32, e17574-e17574.	0.8	1
130	PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL)., 2014, 33, 42-49.		100
131	Influence of genetic variants of genes potentially associated with colorectal brain metastases on overall survival.. Journal of Clinical Oncology, 2014, 32, 487-487.	0.8	0
132	Influence of genetic variants of genes potentially associated with brain metastases on overall survival in 70 colorectal cancer patients.. Journal of Clinical Oncology, 2014, 32, 3565-3565.	0.8	0
133	Tumor-infiltrating lymphocytes (TILs) and expression of PD-L1 in melanoma brain metastases (BM).. Journal of Clinical Oncology, 2014, 32, 9055-9055.	0.8	1
134	Invasion patterns in brain metastases of solid cancers. Neuro-Oncology, 2013, 15, 1664-1672.	0.6	191
135	Optimal Management of Brain Metastases from Breast Cancer. CNS Drugs, 2013, 27, 121-134.	2.7	27
136	Characterization of the inflammatory response to solid cancer metastases in the human brain. Clinical and Experimental Metastasis, 2013, 30, 69-81.	1.7	81
137	Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases. Clinical and Experimental Metastasis, 2013, 30, 357-368.	1.7	66
138	ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. Lung Cancer, 2013, 80, 278-283.	0.9	59
139	Lack of BRAF V600E Protein Expression in Primary Central Nervous System Lymphoma. Applied Immunohistochemistry and Molecular Morphology, 2013, 21, 351-353.	0.6	7
140	Impact of Her-2-Targeted Therapy on Overall Survival in Patients With Her-2 Positive Metastatic Breast Cancer. Breast Journal, 2013, 19, 149-155.	0.4	17
141	Frequent overexpression of ErbB â€” receptor family members in brain metastases of nonâ€”small cell lung cancer patients. Apmis, 2013, 121, 1144-1152.	0.9	15
142	Biology in prevention and treatment of brain metastases. Expert Review of Anticancer Therapy, 2013, 13, 1339-1348.	1.1	9
143	Preoperative Diffusion-Weighted Imaging of Single Brain Metastases Correlates with Patient Survival Times. PLoS ONE, 2013, 8, e55464.	1.1	38
144	Clinical Neuropathology Practice Guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers. , 2013, 32, 148-158.		25

#	ARTICLE	IF	CITATIONS
145	Trial design on prophylaxis and treatment of brain metastases: Lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. <i>European Journal of Cancer</i> , 2012, 48, 3439-3447.	1.3	37
146	Clinical neuropathology practice guide 06-2012: MGMT testing in elderly glioblastoma patients – yes, but how?. , 2012, 31, 405-408.		19
147	Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. <i>Acta Neuropathologica</i> , 2012, 123, 223-233.	3.9	204
148	Clinical Neuropathology Practice News 4-2012: levels of evidence for brain tumor biomarkers. , 2012, 31, 206-209.		8
149	Correlation of large brain edema with favorable prognosis in patients with single brain metastases.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2053-2053.	0.8	0